Navigation Links
Still River Systems, Inc. Secures $33 Million in Private Financing

LITTLETON, Mass., March 17 /PRNewswire/ -- Still River Systems, Inc., a provider of proton therapy solutions, announced today the closing of a private financing round of $33 million co-led by Venrock Associates and existing investor Caxton Health and Life Sciences, with participation by CHL Medical Partners.

Proceeds from this financing will accelerate the development of the company's Monarch250 Proton Therapy System. Still River Systems is committed to advancing the field of radiation treatment by providing an affordable and accessible proton therapy option for cancer patients. Still River Systems' current customers and industry partners include the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine in St. Louis, MO, one of 21 members of the prestigious National Comprehensive Cancer Network and scheduled to install Still River System's first proton therapy system this year. With unprecedented demand for proton therapy in recent years, other pending delivery sites include several of the most technologically advanced and influential providers in the radiation therapy community.

"Completion of this financing illustrates the investment community's confidence in Still River's business model and our ability to execute on our plan," said Marc Buntaine, Chief Executive Officer of Still River Systems. "Given today's economic environment, this strong financial support is a true endorsement of our growing leadership in the radiation therapy marketplace. We are pleased with the continued participation of our existing investors and warmly welcome our new investor partners, Venrock Associates and CHL Medical Partners." In conjunction with this financing, Dr. Anders Hove of Venrock Associates and Dr. Myles Greenberg of CHL Medical Partners will join Still River Systems' Board of Directors.

About Venrock Associates

Venrock is a premier venture capital firm with offices in Palo Alto, New York, Cambridge, MA, and Israel. Originally established as the venture capital arm of the Rockefeller family, Venrock continues a seven-decade tradition of partnering with entrepreneurs to establish successful, enduring companies. For more information, please visit Venrock's website at

About CHL Medical Partners

CHL Medical Partners is a premier venture capital firm dedicated to partnering with entrepreneurs and inventors to create and finance innovative biotechnology, molecular diagnostic, healthcare service and medical device companies. For more information, visit

About Still River Systems

Still River Systems, based in Littleton, Massachusetts, is dedicated to providing physicians, and their patients, access to high quality, cost-effective proton therapy solutions. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment. The Monarch250 has not been cleared by the US Food and Drug Administration for clinical use. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit

SOURCE Still River Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
2. PreMD Reduces Staffing, Operations - FDA Appeal Still in Process
3. New survey: Flu Shot Still not Catching on, Especially at Retail Clinics
4. New study finds blacks still lag in obtaining total knee replacements for arthritis
5. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
6. Cancer death rates dropping among African Americans but survival rates still low
7. Metoprolol Succinate Recalled: Brand Name Drug Scarce But Still Available at Low Cost from Other Countries, Announces
8. Salmonella Infection Numbers Still Rising; Recalls Rise Also
9. Salmonella Infection Numbers Still Rising
10. Photos: Despite Widespread Awareness, Most Women Still Dont Feel at Risk for Cervical Cancer
11. Officials Still Seek Source of Salmonella Outbreak
Post Your Comments:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: